Literature DB >> 30965099

Barriers to the adoption of ventilator-associated events surveillance and prevention.

M Klompas1.   

Abstract

The CDC expanded the purview of safety surveillance for ventilated patients from ventilator-associated pneumonia (VAP) to ventilator-associated events (VAE) in 2013. CDC created VAE definitions to simplify surveillance, increase objectivity, and broaden prevention efforts. Many U.S. hospitals are conducting VAE surveillance but uptake beyond the U.S. has been limited. Review of recent publications suggest three major barriers to the adoption of VAE surveillance and prevention: 1) ongoing uncertainty about VAE and concern about its limited overlap with clinically-defined VAP, 2) a paucity of studies defining risk factors for VAEs and how best to prevent VAEs, and 3) lack of emphasis on VAE surveillance and prevention by regulatory agencies. Emerging data partially address the first two points. Possible VAPs missed by VAE surveillance are associated with lower mortality rates than VAEs and have similar outcomes whether treated with ≤3 days of antibiotics or more conventional courses, suggesting VAE focuses surveillance on severe events. Potentially-modifiable VAE risk factors include deep sedation, positive fluid balance, blood transfusions, and mandatory modes of mechanical ventilation with high inspiratory pressures. Potential interventions to prevent VAEs include avoiding intubation, minimizing sedation, paired daily spontaneous awakening and breathing trials, conservative fluid management, conservative transfusion thresholds, low tidal volume ventilation, and early mobility. There are important limitations to all existing prevention studies, however, and no study has thus far has tested a VAE prevention bundle that includes all these interventions. Further work is needed to better define the clinical significance of VAPs missed by VAE surveillance, to rigorously evaluate the impact of an optimized VAE prevention bundle on VAEs and other outcomes, and to weigh whether these additional data provide adequate evidence to support mandating VAE surveillance and prevention.
Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  prevention; quality improvement; surveillance; ventilator-associated events ventilator-associated pneumonia

Mesh:

Year:  2019        PMID: 30965099     DOI: 10.1016/j.cmi.2019.03.027

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  4 in total

1.  The epidemiology and clinical outcomes of ventilator-associated events among 20,769 mechanically ventilated patients at intensive care units: an observational study.

Authors:  Zhiyong Zong; Xin Sun; Qiao He; Wen Wang; Shichao Zhu; Mingqi Wang; Yan Kang; Rui Zhang; Kang Zou
Journal:  Crit Care       Date:  2021-02-02       Impact factor: 9.097

2.  Fluid Balance and Ventilator-Associated Events Among Patients Admitted to ICUs in China: A Nested Case-Control Study.

Authors:  Wen Wang; Shichao Zhu; Qiao He; Mingqi Wang; Yan Kang; Rui Zhang; Peng Ji; Kang Zou; Michael Klompas; Zhiyong Zong; Xin Sun
Journal:  Crit Care Med       Date:  2022-02-01       Impact factor: 9.296

3.  Associations Between Antithrombosis and Ventilator-Associated Events, ICU Stays, and Mortality Among Mechanically Ventilated Patients: A Registry-Based Cohort Study.

Authors:  Mingqi Wang; Wen Wang; Xue Jia; Qiao He; Shichao Zhu; Yan Kang; Rui Zhang; Yan Ren; Ling Li; Kang Zou; Zhiyong Zong; Xin Sun
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

4.  Sustained reduction of healthcare-associated infections after the introduction of a bundle for prevention of ventilator-associated pneumonia in medical-surgical intensive care units.

Authors:  Carlos Magno Castelo Branco Fortaleza; Sebastião Pires Ferreira Filho; Marina de Oliveira Silva; Sandra Mara Queiroz; Ricardo de Souza Cavalcante
Journal:  Braz J Infect Dis       Date:  2020-09-16       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.